Boston Scientific Corporation (BSX) – What Are Investment Firms Saying About This Stock?

Shares of Boston Scientific Corporation (NYSE:BSX) have received a consensus rating of “Moderate Buy” from the thirty-one research firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation, twenty have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $61.43.

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. Barclays lowered their price target on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a report on Friday. Piper Sandler cut their price objective on shares of Boston Scientific from $65.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 29th. Royal Bank Of Canada decreased their target price on shares of Boston Scientific from $70.00 to $52.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Jefferies Financial Group cut shares of Boston Scientific from a “buy” rating to a “hold” rating and decreased their price objective for the company from $60.00 to $46.00 in a report on Wednesday.

Boston Scientific Stock Performance

Shares of BSX opened at $41.93 on Friday. Boston Scientific has a 1 year low of $39.57 and a 1 year high of $105.65. The company has a market cap of $60.77 billion, a price-to-earnings ratio of 17.77, a price-to-earnings-growth ratio of 1.03 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The firm has a fifty day moving average of $44.78 and a 200-day moving average of $56.88.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the previous year, the firm posted $0.75 earnings per share. The business’s revenue was up 1.4% on a year-over-year basis. As a group, equities analysts anticipate that Boston Scientific will post 3.17 earnings per share for the current year.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

Insiders Place Their Bets

In other news, Director David Habiger acquired 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Michael Mahoney purchased 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 189,522 shares of company stock worth $9,157,810 in the last three months. Company insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perigon Wealth Management LLC bought a new position in shares of Boston Scientific during the second quarter valued at $883,000. Y Intercept Hong Kong Ltd lifted its holdings in Boston Scientific by 148.8% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after purchasing an additional 670,060 shares during the last quarter. Wealthfront Advisers LLC acquired a new position in Boston Scientific in the second quarter valued at about $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab boosted its position in Boston Scientific by 9.9% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after buying an additional 28,961 shares in the last quarter. Finally, Tocqueville Asset Management L.P. bought a new stake in Boston Scientific during the second quarter worth about $38,539,000. 89.07% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.